Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017

The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline ALK inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides a detailed information about discontinued and dormant drugs.

View report: https://arizton.com/reports/pharma-pipeline-analysis/anaplastic-lymphoma-kinase-alk-inhibitors-pipeline-insights

The report profiles key players in developing potential ALK drug candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Scope

Provides in-depth insights about active Anaplastic Lymphoma Kinase (ALK) inhibitors pipeline drug candidates

Offers an extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery

Provides pipeline assessment by monotherapy, combination therapy products, and route of administration

Provides comparative analysis of key marketed and pipeline Anaplastic Lymphoma Kinase (ALK) inhibitors

Includes coverage of detailed pipeline drug profiles, which include product description, chemical information, MOA, licensors and collaborators, development partner

Analyzes key players involved in clinical research and development of the ALK inhibitors

Provides the coverage of key news related to ALK inhibitors, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) belonging to the insulin receptor (IR) superfamily. ALK also known CD246 is encoded by the ALK gene in humans. Immunohistochemical analysis of adult human tissues reveals that ALK expression is sparsely scattered in neural cells, endothelial cells and pericytes in the brain. ALK mRNA is also expressed in the small intestine, testis, prostate, and colon. ALK was initially identified as the product of a gene rearrangement in anaplastic large cell lymphoma (ALCL). ALK was subsequently found to be rearranged, mutated, or amplified in a series of tumors including lymphoma, neuroblastoma, and non-small cell lung cancer (NSCLC). There is strong clinical evidence that ALK is one a key driving factor of oncogenesis, thus making it a key drug target.

Currently marketed ALK inhibitors include Zykadia (ceritinib) and Alecensa (alectinib). These drugs are indicated for the treatment of gastrointestinal cancer and non small cell lung cancer. The ALK inhibitors pipeline has more than 15 molecules and is expected to achieve regulatory approval in foreseeable future, few of which are ensartinib (X-396), X-376, X-390, CEP-28122, EBI-215, EBI-600215, and ASP3026. In pipeline analysis, these are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and pre-clinical stage. Few key companies which are involved in the development of ALK inhibitors include AstraZeneca, Teva, Delenex Therapeutics, Astellas, Amgen and Tesaro.

Reasons to Buy

To gain erudite insights about the ALK inhibitor pipeline landscape

To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine

To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market

To identify competitors and design strategic initiatives for drug development activities

To understand the market and choose right partners for strategic collaborations

To obtain informed updates on drug termination/drug discontinuation

Related Report
Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2017

https://arizton.com/reports/pharma-pipeline-analysis/chimeric-antigen-receptor-car-t-cell-immunotherapy-pipeline-insights-2017

Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.